How should COPD with eosinophilia (blood eosinophil count ≥300 cells/µL) be managed?

Management of Eosinophilic COPD (Blood Eosinophils ≥300 cells/µL)

For symptomatic COPD patients with blood eosinophil counts ≥300 cells/µL who are at high risk of exacerbations, initiate single-inhaler triple therapy (LAMA/LABA/ICS) as first-line maintenance treatment. 1

Treatment Algorithm Based on Clinical Presentation

High-Risk Exacerbators (≥2 moderate or ≥1 severe exacerbation in prior year)

Start with single-inhaler triple therapy (LAMA/LABA/ICS) regardless of current symptom burden when blood eosinophils are ≥300 cells/µL. The 2023 Canadian Thoracic Society guidelines are explicit that triple therapy reduces not only exacerbations but also mortality in this population 1. The IMPACT and ETHOS trials demonstrated that triple therapy reduces annual exacerbation rates to 0.91 events/year compared to 1.21 with LAMA/LABA alone 1.

• ICS dose: Moderate-dose ICS is preferred over high-dose, as ETHOS showed mortality benefit with moderate dosing without additional exacerbation reduction from higher doses 1
• Critical caveat: Do NOT step down or withdraw ICS in patients with eosinophils ≥300 cells/µL, as this significantly increases exacerbation risk 1

If Exacerbations Persist Despite Triple Therapy

Add-on therapies in sequential order:

1. Macrolide maintenance therapy (e.g., azithromycin) - but only after confirming:

   • Normal QT interval on ECG
   • No drug interactions with current medications
   • No evidence of atypical mycobacterial infection 1

2. Consider mepolizumab 100 mg subcutaneously every 4 weeks - The 2025 MATINEE trial demonstrated a 21% reduction in moderate-to-severe exacerbations (rate ratio 0.79) when added to triple therapy in patients with eosinophils ≥300 cells/µL 2. This represents the most recent high-quality evidence for refractory eosinophilic COPD.

3. For chronic bronchitic phenotype: Add roflumilast or N-acetylcysteine 1

Symptomatic Patients Without High Exacerbation Risk

Start with LAMA/LABA dual therapy, then escalate to triple therapy if:

• Symptoms persist despite dual bronchodilation, OR
• Patient develops exacerbations

The presence of eosinophils ≥300 cells/µL lowers the threshold for adding ICS 1.

Key Evidence Considerations

The blood eosinophil threshold of ≥300 cells/µL is strongly supported across multiple evidence streams:

• Exacerbation reduction: Meta-analysis shows rate ratio of 0.57 for ICS continuation at eosinophils >300 cells/µL versus 0.88 at <150 cells/µL (p<0.00001 for difference between groups) 3
• Stability: Blood eosinophil counts are reasonably stable over time (ICC 0.44-0.57), making them reliable for treatment decisions 4
• Pneumonia risk: ICS-associated pneumonia risk is actually LOWER in patients with high eosinophils compared to those with low eosinophils (HR 1.26 in low eosinophil group) 5, suggesting the benefit-risk ratio favors ICS use in this population

Critical Pitfalls to Avoid

1. Never withdraw ICS in patients with eosinophils ≥300 cells/µL - This is explicitly contraindicated even if patients appear stable, as it increases exacerbation risk 1

2. Don't use ICS monotherapy - ICS should only be prescribed in combination with long-acting bronchodilators 1

3. Avoid high-dose ICS - The dose-response curve is flat; moderate doses provide optimal benefit with fewer adverse effects 1

4. Don't ignore the eosinophil count - The GOLD guidelines distinguish that patients with eosinophils <100 cells/µL should receive oral therapies rather than ICS escalation, but at ≥300 cells/µL, ICS-containing regimens are clearly beneficial 1

5. Single-inhaler triple therapy is superior to multiple-inhaler combinations - always prescribe as a single device when possible 1

Monitoring Approach

• Recheck blood eosinophils if considering treatment changes, though single measurements are generally reliable 5, 4
• Sputum eosinophils ≥3% predict higher likelihood of exacerbation remission and may guide de-escalation decisions in select cases 6
• Balance pneumonia surveillance against the documented mortality benefit of ICS-containing therapy in this population 1

The eosinophilic phenotype (≥300 cells/µL) represents a treatable trait in COPD where ICS-containing regimens provide clear mortality and exacerbation benefits that outweigh risks.